Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

NCT ID: NCT04131504

Last Updated: 2024-01-30

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 239 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-10-16
• Study Completion Date: 2023-10-31

Brief Summary

Crohn's disease and ulcerative colitis affect about 1.6 to 3 million people in the United States with many of those being young children and adolescents. Physicians need better ways to inform decisions on therapy selection and recognize ongoing intestinal injury while on treatment.

The main reason for this research study is to see if a blood test or stool test, which measures specific proteins, taken just before starting a new treatment for Crohn's disease can predict a patient's ability to achieve complete intestinal healing. The investigators also want to see if the intensity of gut inflammation can be detected by measuring a separate set of proteins in the blood.

Detailed Description

Despite the heterogeneity of CD phenotypes and a potentially aggressive course of inadequately treated CD, treatment selection for newly diagnosed patients is currently based on clinical factors which do not define CD sub-types. Now, with additional biologic therapies for CD, there is a critical need for individual biochemical analysis both pre-treatment, and following induction to assess the probability of durable remission. These data will inform decisions on continued dosing of the current biologic, or whether addition of combination therapy or switching to a therapy with an alternative mechanism of action will be more beneficial.

The Food & Drug Administration (FDA) defines a companion diagnostic as a device that can identify patients most likely to benefit from a therapy or a device to monitor response with the purpose to adjust the treatment to achieve improved effectiveness.Our global aim is to develop a companion diagnostic (peripheral blood panel) that accurately predicts the probability of deep remission (clinical remission with MH) to anti-TNF and a protein (blood) biomarker panel that reproducibly distinguishes endoscopic MH from active (ulcerated) intestinal inflammation in patients with CD.

The long-term strategy is to utilize the "low-risk" anti-TNF specific module (protein panel) to personalize CD therapy. With the addition of new biologics for CD, patients with a low-risk inflammatory profile would not only be expected to achieve MH but also predicted to respond to treatment escalation strategies while avoiding or stopping the drug (if drug exposure is optimized) sooner in patients in which the protein profile predicts a low probability of deep remission with anti-TNF. As additional therapies are approved for pediatric CD, the priority would be to avoid anti-TNF in patients with a "high-risk" protein profile and specifically select therapies that target the patient's individual inflammatory signature. Additionally, the investigators expect the protein profile of patients failing to achieve deep remission to provide further insight into molecular mechanisms contributing to the continued inflammation and thereby directing the next therapeutic option.

Conditions

Crohn's Disease; IBD

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Phase I - Cross-sectional Study (CD and Suspected IBD)

150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.

No interventions assigned to this group

Phase I - Cross-sectional Study (healthy volunteers)

20 healthy controls will be enrolled at Cincinnati Children's Hospital only. Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.

No interventions assigned to this group

Phase II - Longitudinal Study of Participants with CD

70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.

Infliximab

Intervention Type: DRUG

No standard dosing regimen will be used and the dose will be determined by the treating physician

Adalimumab

Intervention Type: DRUG

No standard dosing regimen will be used and the dose will be determined by the treating physician

Interventions

Infliximab

No standard dosing regimen will be used and the dose will be determined by the treating physician

Intervention Type: DRUG

Adalimumab

No standard dosing regimen will be used and the dose will be determined by the treating physician

Intervention Type: DRUG

Other Intervention Names

Remicade; Humira

Eligibility Criteria

Inclusion Criteria

1. Age criteria: > 1 year to < 22 years of age

2. Diagnosis of Crohn's disease, anti-TNF naïve, and colonoscopy scheduled OR

3. Clinical suspicion for IBD (treatment naïve) and colonoscopy scheduled

4. Permission of parent/guardian and assent or consent of research participant

1. Age criteria: > 1 year to < 22 years of age

2. Any CCHMC patient

3. Permission of parent/guardian and assent or consent of research participant

1. Age criteria: > 1 year to < 22 years of age

2. Diagnosis of Crohn's disease with:

1. Luminal inflammation (ulcerations in ileum and/or colon visible by ileocolonoscopy) and

2. Endoscopic evidence of active Crohn's disease (up to 90 days prior to starting anti-TNF) OR if no colonoscopy within 90 days then fecal calprotectin ≥250 µg/g or fecal lactoferrin >10 µg/g (<90 days from starting anti-TNF)

3. Anti-TNF naïve

4. Starting infliximab or adalimumab (or either biosimilar)

5. Permission of parent/guardian and assent or consent of research participant

Exclusion Criteria

1. Any prior treatment with an anti-TNF, such as infliximab, adalimumab, certolizumab or golimumab

2. Known diagnosis of ulcerative colitis (UC) or inflammatory bowel disease-unspecified (IBD-U)

3. Active or prior evidence of internal (abdominal/pelvic) penetrating fistula(e)

4. Active intra-abdominal abscess or perianal abscess

5. Active Clostridium difficile infection or other known enteric infection in last 2 weeks

6. Current ileostomy or colostomy, extensive small bowel resection, ileoanal pouch or short bowel syndrome

7. History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)

8. Any condition that in the opinion of the PI will prevent the research participant from taking part in this study

Phase I - Cross-sectional Study (healthy volunteers)

1. Known diagnosis of one or more of the following: irritable bowel syndrome, gastroesophageal reflux, constipation, BMI>95% for age, small intestinal bacterial overgrowth (SIBO) or history of intestinal polyps

2. Received any antibiotic in the last 30 days or known viral or bacterial illness in the last 30 days

3. Any NSAID use in the last 14 days

4. History of an autoimmune disease (including diabetes, autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)

5. Any condition that in the opinion of the PI will prevent the research participant from taking part in this study

Phase II - Longitudinal Study of Participants with CD

1. Crohn's disease limited to esophagus, stomach, duodenum or jejunum

2. Prior treatment with infliximab, adalimumab, certolizumab or golimumab

3. Known diagnosis of Ulcerative colitis (UC) or inflammatory bowel disease-unspecified (IBD-U)

4. Active or prior evidence of internal (abdominal/pelvic) penetrating fistula(e)

5. Active intra-abdominal abscess or perianal abscess

6. Active Clostridium difficile infection or other known enteric infection in last 2 weeks

7. Current ileostomy or colostomy, extensive small bowel resection, ileoanal pouch or short bowel syndrome

8. History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)

9. Contraindications to MRI scanning, such as metal implants/non-compatible medical devices or medical conditions

10. Any condition that in the opinion of the PI will prevent the research participant from taking part in this study

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

The Leona M. and Harry B. Helmsley Charitable Trust

OTHER

Sponsor Role: collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Phillip Minar, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital Medical Center, Cincinnati

Locations

Connecticut Children's Medical Center

Hartford, Connecticut, United States

Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Nationwide Children's Hospital

Columbus, Ohio, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Countries

United States

References

Velez Lopez A, Waddell A, Antonacci S, Castillo D, Santucci N, Ollberding NJ, Eshleman EM, Denson LA, Alenghat T. Microbiota-derived butyrate dampens linaclotide stimulation of the guanylate cyclase C pathway in patient-derived colonoids. Neurogastroenterol Motil. 2023 Dec;35(12):e14681. doi: 10.1111/nmo.14681. Epub 2023 Sep 22.

Reference Type: DERIVED

PMID: 37736865 (View on PubMed)

Other Identifiers

2019-0730

Identifier Type: -

Identifier Source: org_study_id